Guanming Jiang

Dr. Guanming Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
SHSida Huang
Sida Huang
HLHanqi Lu
Hanqi Lu
JCJin Chen
Jin Chen
CJChengyi Jiang
Chengyi Jiang
GJGuanming Jiang
Guanming Jiang
LDLi-Er Deng
Li-Er Deng
Renal fibrosis is the result of all chronic kidney diseases and is becoming a major global health hazard.

3 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TAToufiq Ul Amin
Toufiq Ul Amin
RERasha Emara
Rasha Emara
APArindom Pal
Arindom Pal
HAHala Aldawod
Hala Aldawod
GJGuanming Jiang
Guanming Jiang
MAMamoun M. Alhamadsheh
Mamoun M. Alhamadsheh

27 June 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YDYu Deng
Yu Deng
SHSida Huang
Sida Huang
GJGuanming Jiang
Guanming Jiang
LZLuyi Zhou
Luyi Zhou
ANAlireza Nezamzadeh-Ejhieh
Alireza Nezamzadeh-Ejhieh
ZZZhikun Zhou
Zhikun Zhou
Ferroptosis is a programmed cell death mechanism characterized by the accumulation of iron (Fe)-dependent lipid peroxides within cells. Ferroptosis holds excellent promise in tumor therapy. Metal–organic frameworks (MOFs) offer unique advantages in tumor ferroptosis treatment due to their high porosity, excellent stability, high biocompatibility, and targeting capabilities. Inducing ferroptosis in tumor cells primarily involves the production of reactive oxygen species (ROS), like hydroxyl radicals (˙OH), through iron-mediated Fenton reactions. However, the intrinsic H2O2 levels in tumor cells are often insufficient to sustain prolonged consumption, limiting therapeutic efficacy if ˙OH production is inadequate. Therefore, catalyzing or supplementing the intracellular H2O2 levels in tumor cells is essential for inducing ferroptosis by nanoscale metal–organic frameworks. This article reviews the biological characteristics and molecular mechanisms of ferroptosis, introduces H2O2-related substances, and reviews MOF-based nanoscale strategies for enhancing intracellular H2O2 levels in tumor cells. Finally, the challenges and prospects of this approach are discussed, aiming to provide insights into improving the effectiveness of ferroptosis induced by MOFs.

20 May 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
XYXiaojun Yang
Xiaojun Yang
YZYihong Zeng
Yihong Zeng
QTQinquan Tan
Qinquan Tan
ZHZhihua Huang
Zhihua Huang
JJJun Jia
Jun Jia
GJGuanming Jiang
Guanming Jiang
Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. This study aimed to evaluate the efficacy of PD-1/PD-L1 ICIs compared with chemotherapy for patients with lung cancer with BM. Electronic databases (PubMed, Embase, The Cochrane Library, and Web of Science) were searched. The meta-analysis assessed overall survival (OS) and progression-free survival (PFS) of the PD-1/PD-L1 inhibitors axis and its relationship with pathological type, drug modality, and the treatment line number in patients with BM from lung cancer. We included 694 patients with BM from lung cancer from 11 randomized controlled trials. Statistical analysis showed that compared with chemotherapy, PD-1/PD-L1 inhibitors could significantly prolong OS ( hazard   ratio   HR = 0.75 , 95 % confidence   interval   95 % CI = 0.51 – 0.99 ) and PFS ( HR = 0.65 , 95 % CI = 0.51 – 0.80 ). In the subgroup analysis, ICIs plus chemotherapy improved PFS ( HR = 0.60 , 95 % CI = 0.40 – 0.80 ), but not OS ( HR = 0.75 , 95 % CI = 0.30 – 1.19 ). The efficacy of ICI monotherapy in patients with BM was significantly different between OS and PFS: OS pooled HR = 0.81 ( 95 % CI = 0.57 – 1.05 ) and PFS = 0.78 ( 95 % CI = 0.62 – 0.94 ). Among different pathological types, the OS pooled HR was 0.67 (9 5 % CI = 0.39 – 0.95 ) for non-small cell lung cancer (NSCLC) and 0.94 ( 95 % CI = 0.56 – 1.33 ) for small cell lung cancer (SCLC); the PFS pooled HR was 0.58 ( 95 % CI = 0.39 – 0.76 ) for NSCLC and 0.79 ( 95 % CI = 0.65 – 0.93 ) for SCLC. Subgroups analysis of treatment line showed that no advantage for OS with ICIs as first-line or subsequent-line therapy, whereas ICIs as first-line ( HR = 0.63 , 95 % CI = 0.53 – 0.74 ) and second-line ( HR = 0.62 , 95 % CI = 0.62 – 0.96 ) benefitted PFS. This meta-analysis implied that compared with chemotherapy, PD-1/PD-L1 inhibitors significantly improved efficacy treatment of patients with BM from lung cancer. Further studies are needed to confirm the role of ICIs in different pathological types and drug treatment modalities.

1 July 2023 in Panminerva Medica
Verified
Journal Article
Closed access
PLPingping Lin
Pingping Lin
QLQingshan Li
Qingshan Li
XLXiying Lv
Xiying Lv
JQJie Qu
Jie Qu
DWDongjuan Wang
Dongjuan Wang
GJGuanming Jiang
Guanming Jiang
Article: HMGA1 promotes the development of esophageal squamous cell carcinoma by mediating miR-671-5p/lncRNA DLEU1 - Panminerva Medica 2020 Jan 30 - Minerva Medica - Journals

20 November 2025 in ESMO Open
Verified
Journal Article
Open access
MLM. Li
M. Li
YPY. Pan
Y. Pan
GJGuanming Jiang
Guanming Jiang
QWQ. Wang
Q. Wang
GWG. Wu
G. Wu
LCLikun Chen
Likun Chen
There is a lack of prospective randomized controlled trials of antiangiogenic therapy in patients with brain metastases. We conducted this phase III, randomized, multicenter study (BAP BRAIN) to evaluate the intracranial efficacy and safety of bevacizumab plus chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) and brain metastases, and provide evidence for this previously unexplored subgroup. Treatment-naïve, non-squamous NSCLC patients with confirmed brain metastases and without sensitizing epidermal growth factor receptor or anaplastic lymphoma kinase mutations were screened from 11 centers in China. The eligible patients were randomly assigned (1 : 1) to receive bevacizumab plus pemetrexed-platinum or pemetrexed-platinum for four to six cycles, followed by bevacizumab plus pemetrexed or pemetrexed maintenance until disease progression, unacceptable toxicity, or death. The primary endpoint was intracranial progression-free survival (iPFS), and secondary endpoints included PFS, overall survival (OS), intracranial objective response rate (iORR), systemic ORR, and safety. A total of 160 patients were eligible and underwent randomization, and 153 patients received at least one dose of drug and were included in the full analysis set. After a median follow-up of 16.8 months, the median iPFS was 11.07 months in the bevacizumab plus pemetrexed-platinum group versus 7.37 months in the pemetrexed-platinum group [hazard ratio (HR) 0.494, P < 0.001]. Similarly, the median systemic PFS was significantly longer with bevacizumab plus pemetrexed-platinum than with pemetrexed-platinum alone (8.77 months versus 5.23 months, HR 0.540, P < 0.001). The bevacizumab plus pemetrexed-platinum group had better iORR (69.6% versus 32.4%) and ORR (58.2% versus 27.0%) and remission rate of cerebral edema (88.9% versus 41.9%) than the pemetrexed-platinum group. At data cut-off, the median OS was 28.07 months in the bevacizumab plus pemetrexed-platinum group versus 18.53 months in the pemetrexed-platinum group (HR 0.752, P = 0.162). There was no grade ≥3 intracranial hemorrhage, and most of the adverse events were manageable. This study demonstrated encouraging intracranial efficacy and acceptable safety of bevacizumab plus chemotherapy in patients with non-squamous NSCLC and brain metastases in the first-line setting.